Navigation Links
Pfizer and Medivation Initiate Phase 3 Trial of Dimebon Added to Donepezil in Patients with Alzheimer's Disease
Date:4/15/2009

E: This press release contains forward-looking statements, including statements regarding the timing of: initiation of clinical studies, filing of an NDA for Dimebon, the presentation of data with respect to Dimebon and the receipt of milestone payments as well as the extent of future expected financial results, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements involve risks and uncertainties that could cause Medivation's actual results to differ significantly from those projected, including, without limitation, risks related to progress, timing and results of Medivation's clinical trials, difficulties or delays in obtaining regulatory approval, enrollment of patients in Medivation's clinical trials, partnering of Medivation's product candidates, manufacturing of Medivation's product candidates, competition with Medivation's product candidates should they receive marketing approval, the adequacy of Medivation's financial resources, unanticipated expenditures or liabilities, intellectual property matters, and other risks detailed in Medivation's filings with the Securities and Exchange Commission, including its annual report on Form 10-K for the year ended December 31, 2008 filed March 16, 2009, with the SEC. You are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date of this release. Medivation disclaims any obligation or undertaking to update or revise any forward-looking statements contained in this press release.


'/>"/>
SOURCE Pfizer Inc; Medivation, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Pfizer Contributes Critical Data to URMC Drug Safety Initiative
2. Medarex Receives Milestone Payment from Pfizer for Investigational New Drug Application Filing
3. Silence Therapeutics to Receive $1.9m Milestone Payment as Pfizer and Quark Commence Phase II Trial
4. Quark Pharmaceuticals Announces First Patient Dosing by Pfizer in Phase II Trial of RNAi Therapy in Diabetic Macular Edema
5. MannKind Addresses Pfizers Announcement Regarding Exubera
6. Tacere Therapeutics Enters Collaboration and License Agreement With Pfizer To Develop and Commercialize RNAi Hepatitis C Drug
7. NicOx Announces Pfizer Initiates Phase 2 Clinical Development for PF-03187207 in Japan
8. Rigel Announces Initiation of Phase 1 Clinical Trial of R343 for Allergic Asthma by its Partner Pfizer
9. Coley Pharmaceutical Group and Pfizer Nominate Additional Anti-Cancer Compound for Clinical Development
10. Kosans Motilin Receptor Agonist, Licensed to Pfizer, Enters Phase 1 Clinical Trial in Gastroesophageal Reflux Disease
11. Wyeths Torisel and Roche/Genentechs Avastin Will Challenge Pfizers Sutent to Become the Clinical Gold Standard for Treatment of Metastatic Renal Cell Carcinoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... 2014   Health 2.0 announces Bernard Tyson ... physicians Eric Topol , Patrick Soon-Shiong , and ... 2.0 8th Annual Fall Conference this coming Sept. 21-24 ... Health 2.0 is set to host the very first Wearable ... on Consumer Tech & Wearables: Powering Healthy Lifestyles. ...
(Date:7/29/2014)...   , First patient ... efficacy and safety of MSB0010718C in patients with metastatic Merkel ... aggressive skin cancer lacking effective treatments   MSB0010718C is ... clinical trial for the treatment of solid tumors that aims ... a subsidiary of Merck KGaA, Darmstadt, Germany ...
(Date:7/28/2014)... , July 28, 2014  Dignity Health ... has received the Get With The Guidelines®-Stroke Silver-Plus ... measures outlined by the American Heart Association/American Stroke ... is the number four cause of death and ... the United States , according to ...
Breaking Medicine Technology:Kaiser Permanente CEO to Keynote Health 2.0 8th Annual Fall Conference 2Kaiser Permanente CEO to Keynote Health 2.0 8th Annual Fall Conference 3EMD Serono Initiates Phase II Study of Anti-PD-L1 Antibody MSB0010718C in Metastatic Merkel Cell Carcinoma 2EMD Serono Initiates Phase II Study of Anti-PD-L1 Antibody MSB0010718C in Metastatic Merkel Cell Carcinoma 3EMD Serono Initiates Phase II Study of Anti-PD-L1 Antibody MSB0010718C in Metastatic Merkel Cell Carcinoma 4EMD Serono Initiates Phase II Study of Anti-PD-L1 Antibody MSB0010718C in Metastatic Merkel Cell Carcinoma 5Dignity Health St. Mary's Medical Center Honored with Quality Achievement Award for Stroke Care 2Dignity Health St. Mary's Medical Center Honored with Quality Achievement Award for Stroke Care 3
... --Could Become First Effective Drug for Rare Genetic ... have used,a drug to achieve normal levels of ... high insulin levels. If this approach,succeeds in humans, ... congenital hyperinsulinism, a rare but potentially devastating genetic,disease ...
... First to Receive FDA, Clearance for Diagnosis of Uncertain Tumors; ... ... July 31 Pathwork Diagnostics, Inc.,a molecular diagnostics company focused on ... cleared its Pathwork(R),Tissue of Origin Test for use in determining the ...
Cached Medicine Technology:Treatment Corrects Severe Insulin Imbalance in Animal Studies 2Treatment Corrects Severe Insulin Imbalance in Animal Studies 3FDA Clears the Pathwork(R) Tissue of Origin Test for Hard-To-Identify Tumors 2FDA Clears the Pathwork(R) Tissue of Origin Test for Hard-To-Identify Tumors 3FDA Clears the Pathwork(R) Tissue of Origin Test for Hard-To-Identify Tumors 4
(Date:7/29/2014)... should significantly reform the federal system for financing ... the public,s $15 billion annual investment is producing ... new report by the Institute of Medicine. ... requires little accountability, allocates funds independent of workforce ... to train physicians in the health care settings ...
(Date:7/29/2014)... July 29, 2014 Frank Davis, Activz ... can help parents add nutrition to their kids’ meals ... – Key market drivers in kids’ foods market” by ... pleased to announce the interview Frank Davis had with ... Activz organic vegetable and fruit produce powders to kids ...
(Date:7/29/2014)... health institutions, including Penn State College of Medicine, ... and expand a health data research network., The ... through the Patient Protection and Affordable Care Act, ... Pittsburgh, Temple University and Johns Hopkins University -- ... four universities have come together to create a ...
(Date:7/29/2014)... According to a new report series ... authority in medical device market research, the Global ... $8 billion by 2018. This growth will be ... heart valve market, which is comprised of both the ... valve repair (TMVR) segments. , There are many risks ...
(Date:7/29/2014)... the Elizabeth Glaser Pediatric AIDS Foundation (EGPAF) and the ... improve access to essential pain medications for people living ... Treat the Pain initiative, this new partnership will help ... services throughout the country. , Swaziland has the ... 26 percent of adults ages 15-49 infected. Many of ...
Breaking Medicine News(10 mins):Health News:$15 billion annual public funding system for doctor training needs overhaul, says IOM 2Health News:$15 billion annual public funding system for doctor training needs overhaul, says IOM 3Health News:Activz Organic Fruit and Vegetable Produce Powders and Founder Frank Davis Mentioned in WholeFoods Magazine Article 2Health News:Activz Organic Fruit and Vegetable Produce Powders and Founder Frank Davis Mentioned in WholeFoods Magazine Article 3Health News:New network unites university health care research 2Health News:Global Transcatheter Heart Valve Devices Market Outlook to 2018: Breakthrough Developments led by Abbott, Edwards LifeSciences and Medtronic 2Health News:Global Transcatheter Heart Valve Devices Market Outlook to 2018: Breakthrough Developments led by Abbott, Edwards LifeSciences and Medtronic 3Health News:New partnership to improve access to essential pain medications for people living with HIV 2
... quality of life, study finds , , SATURDAY, March ... tea and acupuncture, may safely and effectively help ... Use of Erka Shizheng Herbal Tea, a bath ... the severity of the itchy, red skin condition and ...
... MINNEAPOLIS, March 13 HealthFitness Corporation (NYSE ... health and productivity management solutions, announced today that Gregg ... Winnekins, chief financial officer, will present at the B. ... Conference on Thursday, March 19, 2009 at 11:00 a.m. ...
... Cardiovascular Institute achieves milestone outcomes for heart transplantCHICAGO, ... United Network of Organ Sharing (UNOS) shows that ... achieved the largest volumes and top-rated outcomes in ... among the top 20 heart transplant programs nationally. ...
... ovary removal is another reproductive factor linked to cardiovascular ... -- The things that affect a woman,s reproductive health ... research shows. , Giving birth prematurely or delivering a ... of cardiovascular disease in the mother, according to two ...
... 13 Stryker Corporation (NYSE: SYK ) announced today that ... that will be held:, April ... Radisson Plaza Hotel, ... both the audio and the video presentation from the meeting, is available ...
... In the ongoing effort to ensure physician and ... (ABMS) is convening consumer, legislative and purchaser stakeholders for ... ABMS is the not-for-profit organization that oversees U.S. ... at the forum are Janet M. Corrigan, PhD, MBA, ...
Cached Medicine News:Health News:Northwestern Memorial's Heart Transplant Program No. 1 in Illinois and Among Highest-Rated Nationally 2Health News:Northwestern Memorial's Heart Transplant Program No. 1 in Illinois and Among Highest-Rated Nationally 3Health News:Preemie Delivery Tied to Later Heart Woes for Women 2Health News:Preemie Delivery Tied to Later Heart Woes for Women 3Health News:Stryker to Provide Webcast and Telephone Access to Annual Shareholder Meeting 2Health News:ABMS Hosts First National Health Policy Forum to Address Physician Accountability and Health System Performance Standards 2Health News:ABMS Hosts First National Health Policy Forum to Address Physician Accountability and Health System Performance Standards 3
... ACMI™ USA Elite System Rotating Continuous Flow ... the urologist to rotate the working element ... of the sheaths. The result no ... tangled tubing due to rotating flow ports, ...
... PC-based ECG device that can be ... an innovative software. The system enables ... using a standard 12-lead setup that ... software includes two applications: Rest ECG ...
Used for traversing and exploring urethral strictures. The malleable tip can be shaped to desired configuration. The proximal end is threaded to attach to standard followers. Supplied sterile in peel...
The removable inflation adapter allows the ureteroscope to be removed after the catheter is in place. Supplied sterile in peel-open packages. Intended for one-time use....
Medicine Products: